ACADIA Pharmaceuticals Inc

ACAD remains in a Stage 2 advancing regime, but signs of short-term exhaustion are emerging at new highs. Price is extended well above rising EMAs and the 200 DMA, with the Bullish Exhaustion pattern and extreme overbought readings suggesting elevated risk of a pullback. No Lockout Rally override is active, so execution should be deferred; stalk for a pullback into the dynamic support zone around the 9 and 20 EMAs for optimal entry.

• ↑Q1 revenue $268M (+11% YoY) driven by Debut $101M (+20%) and New Plaza $167M (+6%)
• ↑Positive CHMP opinion for Daybu in Rett syndrome; pipeline peak sales potential ~$11B
• ↓CHMP issued negative trend vote on Drafinitide, risking EU approval and timelines